文献速递垂体与肾上腺疾病

非功能性肾上腺腺瘤患者死亡率未增加:一项匹配队列研究

Mortality Not Increased in Patients With Nonfunctional Adrenal Adenomas: A Matched Cohort Study.
PubMed 文献 · J Clin Endocrinol Metab · 2023-01-01

这项回顾性匹配队列研究纳入瑞典南部2个内分泌中心2005至2015年转诊的肾上腺偶发瘤患者1154例及按性别、年龄和居住地3:1匹配的对照3462例,中位随访6.6年。非功能性肾上腺腺瘤患者死亡率与对照无统计学显著差异(HR 1.13 [0.87-1.46]),而皮质醇DST 83-137 nmol/L(HR 1.99 [1.38-2.88])和≥138 nmol/L(HR 4.09 [2.41-6.93])患者死亡率较对照增加。

要点

  • 非功能性肾上腺腺瘤患者全因死亡率与匹配对照无统计学显著差异(HR 1.13 [0.87-1.46])。
  • 皮质醇DST 83-137 nmol/L患者死亡率较对照增加(HR 1.99 [1.38-2.88])。
  • 皮质醇DST≥138 nmol/L患者死亡率较对照增加(HR 4.09 [2.41-6.93])。

核心结论

  • 非功能性肾上腺腺瘤似乎不构成肾上腺偶发瘤患者死亡率增加的临床相关风险,而轻度自主皮质醇分泌患者、尤其是年轻患者和皮质醇DST≥83 nmol/L者,与匹配对照相比死亡率风险显著增加。

研究设计与样本

  • 回顾性匹配队列研究,纳入2005至2015年转诊至瑞典南部2个内分泌中心的肾上腺偶发瘤患者1154例,并按性别、年龄和居住地3:1匹配对照3462例。

主要发现

  • 中位随访6.6年期间,210例患者和505例对照死亡。
  • 非功能性肾上腺腺瘤患者与对照相比死亡率无统计学显著差异(HR 1.13 [0.87-1.46])。
  • 皮质醇DST 83-137 nmol/L患者死亡率较对照增加(HR 1.99 [1.38-2.88])。
  • 皮质醇DST≥138 nmol/L患者死亡率较对照增加(HR 4.09 [2.41-6.93])。
  • 年龄小于65岁且皮质醇DST 50-82 nmol/L的患者死亡率较对照增加(HR 2.33 [1.30-4.17])。

关键数值与推荐

  • 患者按1 mg地塞米松抑制试验后皮质醇水平(cortisolDST)分组:<50 nmol/L(非功能性肾上腺腺瘤)、50-82 nmol/L、83-137 nmol/L和≥138 nmol/L。
  • 主要终点为全因死亡率,结局数据来自死亡原因登记处。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Mild autonomous cortisol secretion (MACS) is associated with increased mortality in patients with adrenal incidentalomas, but little is known regarding the potential risk associated with nonfunctional adrenal adenomas (NFAA), which constitute the majority of adrenal incidentalomas. OBJECTIVE: Compare mortality risk in patients with NFAA, and different levels of MACS, to matched controls. METHOD: This was a retrospective matched cohort study. All patients referred to 2 endocrine centers in southern Sweden because of an adrenal incidentaloma between 2005 and 2015 were enrolled. Controls (3:1) matched for sex, age, and residency were included. Primary endpoint was all-cause mortality. Outcome data were obtained from the Cause of Death Register. Patients were grouped according to cortisol level post 1-mg dexamethasone suppression test (cortisolDST) (<50 (NFAA), 50-82, 83-137, and ≥138 nmol/L). RESULTS: 1154 patients and 3462 matched controls were included. During a median follow-up of 6.6 years, 210 patients and 505 controls died. There were no statistically significant differences in mortality between patients with NFAA and their controls (HR 1.13 [0.87-1.46]) whereas mortality was increased compared to controls in patients with cortisolDST 83-137 (HR 1.99 [1.38-2.88]) and ≥138 nmol/L (HR 4.09 [2.41-6.93]). Likewise, the mortality risk was increased in patients younger than 65 years with cortisolDST 50-82 nmol/L compared with controls (HR 2.33 [1.30-4.17]). CONCLUSION: NFAA does not seem to pose a clinically relevant risk for increased mortality in patients with adrenal incidentalomas while patients with MACS, and especially younger patients and those with cortisolDST ≥83 nmol/L, have significantly increased mortality risk compared with matched controls.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Kjellbom A, Lindgren O, Danielsson M, et al. Mortality Not Increased in Patients With Nonfunctional Adrenal Adenomas: A Matched Cohort Study. J Clin Endocrinol Metab. 2023. PMID: 36800277. doi:10.1210/clinem/dgad074

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。